secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001193125-24-161087
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs reports 67% ORR in HR-MDS, 43% in TP53m AML from SL-172154 Phase 1B
--------------------------------------------------------------------------------

- Observed 67% ORR in frontline HR-MDS patients (24 treated), with 42% complete remission rate; median survival not yet reached.
- In 21 frontline TP53m AML patients, ORR 43% with 29% CR; median survival not reached; 5 patients bridged to transplant.
- Manageable safety: no grade 3+ IRRs with dexamethasone premedication; no hemolytic anemia; deaths unrelated to SL-172154.
- Company focusing later-stage development on HR-MDS and TP53m AML; no further PROC development due to competitive landscape.
- Enrollment underway for randomized controlled HR-MDS cohort; regulatory discussions expected later this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000119312524161087/0001193125-24-161087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000119312524161087/d841424d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-161087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer